scholarly journals Guidelines for the treatment of abdominal aortic aneurysms: Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery

2003 ◽  
Vol 37 (5) ◽  
pp. 1106-1117 ◽  
Author(s):  
David C. Brewster ◽  
Jack L. Cronenwett ◽  
John W. Hallett ◽  
K.Wayne Johnston ◽  
William C. Krupski ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
American Association ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Abdominal Aortic

scholarly journals The Impact of Endovascular Repair of Abdominal Aortic Aneurysms on Vascular Surgery Training in Open Aneurysm Repair

2021 ◽  
Vol 74 (3) ◽  
pp. e158-e159
Author(s):  
Nadin Elsayed ◽  
Maryam A. Khan ◽  
Isaac Naazie ◽  
Jaideep Das Gupta ◽  
Randall De Martino ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
Endovascular Repair ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Surgery Training ◽  
Abdominal Aortic ◽  
Aneurysm Repair ◽  
The Impact

Abdominal aortic aneurysms

2021 ◽  
pp. 1-7
Author(s):  
Aadil Ahmed ◽  
Adam Heyes ◽  
Jagraj Pandher ◽  
Sriram Rajagopalan
Keyword(s):  
Vascular Surgery ◽  
European Society ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Substantial Proportion ◽  
Limb Loss ◽  
Diagnosis And Management ◽  
Abdominal Aortic ◽  
The Uk ◽  
Treatable Condition

Vascular surgery is a relatively new surgical sub-speciality in the UK, with treatment of abdominal aortic aneurysms forming a substantial proportion of the emergency and elective caseload. This article summarises the guidance from the National Institute of Health and Care Excellence and the European Society for Vascular Surgery that outlines the epidemiology, diagnosis and management of abdominal aortic aneurysms. This is important for both vascular and non-vascular trainees to understand because of the critical nature of the disease, which can cause catastrophic haemorrhage, limb loss and mortality. However, if discovered in time, abdominal aortic aneurysms are a very treatable condition.

scholarly journals Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures

2008 ◽  
Vol 136 (7-8) ◽  
pp. 367-372 ◽  
Author(s):  
Igor Koncar ◽  
Nebojsa Savic ◽  
Lazar Davidovic ◽  
Dusica Simic ◽  
Dejan Markovic ◽  
...  
Keyword(s):  
Portal Hypertension ◽  
Vascular Surgery ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Factor Vii ◽  
Activated Factor Vii ◽  
Group I ◽  
Abdominal Aortic ◽  
Retroperitoneal Tumors ◽  
Ruptured Abdominal Aortic Aneurysms

INTRODUCTION A recombinant form of activated factor VII (rFVIIa) is a haemostatic drug that is approved for use in haemophiliacs with antibodies to factor VIII or factor IX. Most recent studies and clinical experience have shown that rFVIIa (NovoSeven ?, Novo Nordisk A/S, Denmark) gives extreme haemostatic effect in patients with severe "non-haemophilic" bleeding produced after trauma and major surgery. OBJECTIVE We present our preliminary experience of the use of rFVIIa in vascular surgery when conventional haemostatic measures are inadequate. METHOD There were 32 patients divided into five groups: Group I - 14 patients with ruptured abdominal aortic aneurysms; Group II - 10 patients with thoracoabdominal aortic aneurysms; Group III - 5 patients with retroperitoneal tumors involving great abdominal vessels; Group IV - 2 patients with portal hypertension and Group V - one patient with iatrogenic injury of brachial artery and vein during fibrinolytic treatment, because of myocardial infarction. RESULTS Clinical improvement was detected following treatment in 29 patients. Bleeding was successfully controlled as evidenced by improved haemodynamic parameters and decreased inotropic and transfusion requirements. CONCLUSION In vascular patients more liberal use of rFVIIa is limited, because no randomized controlled trial has proved its efficacy and safety in such patients; while also keeping in mind that the price of a 4.8 mg of rFVIIa is $4,080. We recommend the use of rFVIIa in vascular surgery only during and after operative treatment of thoracoabdominal aortic aneurysms, ruptured abdominal aortic aneurysms, retroperitoneal tumors involving the aorta and/or inferior vena cava, as well as portal hypertension, when non-surgical massive uncontrolled bleeding are present.

scholarly journals Screening for abdominal aortic aneurysms in Canada: 2020 review and position statement of the Canadian Society for Vascular Surgery

2021 ◽  
Vol 64 (5) ◽  
pp. E461-E466
Author(s):  
Varun Kapila ◽  
Prasad Jetty ◽  
Doug Wooster ◽  
Vic Vucemilo ◽  
Luc Dubois ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
Abdominal Aortic Aneurysms ◽  
Position Statement ◽  
Aortic Aneurysms ◽  
Canadian Society ◽  
Screening Guidelines ◽  
Abdominal Aortic ◽  
Canadian Population ◽  
Level 1 ◽  
Société Canadienne

Abdominal aortic aneurysms (AAAs) remain a major risk to patients, despite level 1 evidence for screening to prevent rupture events and decrease mortality. In 2007, the Canadian Society for Vascular Surgery (CSVS) published a review and position statement for AAA screening in Canada. Since that publication, there have been a number of updates in the published literature affecting screening recommendations. In this paper, we present a review of some of the controversies in the AAA screening literature to help elucidate differences in the various published screening guidelines. This article represents a review of the data and updated recommendations for AAA screening in the Canadian population on behalf of the CSVS. Les anévrismes de l’aorte abdominale (AAA) continuent de poser un risque majeur pour les patients, malgré des données probantes de niveau 1 à l’appui du dépistage pour prévenir les ruptures et réduire la mortalité. En 2007, la Société canadienne de chirurgie vasculaire (SCCV) a publié une revue et un énoncé de position sur le dépistage de l’AAA au Canada. Depuis lors, plusieurs mises à jour ont paru dans la littérature et elles ont un impact sur les recommandations relatives au dépistage. Dans le présent article, nous présentons une synthèse de quelques controverses soulevées dans la littérature sur le dépistage de l’AAA afin d’expliquer les différences entre les diverses lignes directrices publiées à ce sujet. Cet article propose au nom de la SCCV une revue des données probantes et des recommandations à jour sur le dépistage de l’AAA dans la population canadienne.

scholarly journals Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures

2008 ◽  
Vol 136 (Suppl. 3) ◽  
pp. 199-203 ◽  
Author(s):  
Igor Koncar ◽  
Nebojsa Savic
Keyword(s):  
Vascular Surgery ◽  
Vena Cava ◽  
Abdominal Aortic Aneurysms ◽  
Factor Ix ◽  
Aortic Aneurysms ◽  
Factor Vii ◽  
Activated Factor Vii ◽  
Group I ◽  
Abdominal Aortic ◽  
Ruptured Abdominal Aortic Aneurysms

INTRODUCTION. Recombinant form of activated factor VII (rFVIIa) has been approved for use in haemophiliacs with antibodies to factor VIII or factor IX. Recent studies and clinical experiences have showed that rFVIIa gives extreme haemostatic effects in patients with severe ?nonhaemophilic? bleeding produced after trauma and major surgery. OBJECTIVE. We present our preliminary experience of the use of rFVIIa in vascular surgery where conventional haemostatic measures were inadequate. METHOD. There were 17 patients divided into three groups: Group I - 6 patients with ruptured abdominal aortic aneurysms; Group II - 7 patients with thoracoabdominal aortic aneurysms and 1 patient with acute complicated dissection of thoracic aorta type III; Group III - 3 patients with retroperitoneal tumours involving great abdominal vessels. RESULTS. Clinical improvement was reported following the treatment in 14 of 17 patients in our study. Bleeding was successfully controlled as evidenced by improved haemodynamic parameters and decreased inotrope and transfusion requirement. CONCLUSION. More liberal use of rFVIIa in vascular patients is limited, because there is no randomized controlled trial proving efficacy and safety in vascular patients. We recommend the use of rFVIIa in vascular surgery only during and after operative treatment of thoracoabdominal aortic aneurysms, ruptured abdominal aortic aneurysms and retroperitoneal tumours involving aorta and/or inferior vena cava complicated with ?non-surgical? massive uncontrolled bleeding.

scholarly journals PREVALENCE 38 OF ABDOMINAL AORTIC ANEURYSMS IN A RISK POPULATION SEEN IN A VASCULAR SURGERY DEPARTMENT

Angiología ◽  
2019 ◽  
Author(s):  
Estrella Blanco Cañibano ◽  
pilar caridad morata barrado ◽  
Miguel Muela Méndez ◽  
Beatriz Garcia Fresnillo ◽  
Mercedes Guerra Requena
Keyword(s):  
Vascular Surgery ◽  
Abdominal Aortic Aneurysms ◽  
Aortic Aneurysms ◽  
Risk Population ◽  
Abdominal Aortic ◽  
Surgery Department
Sign in / Sign up

Export Citation Format

Share Document